These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 32961833

  • 21. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
    Isla A, Canut A, Arribas J, Asín-Prieto E, Rodríguez-Gascón A.
    Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.
    Chaijamorn W, Charoensareerat T, Srisawat N, Pattharachayakul S, Boonpeng A.
    J Intensive Care; 2018 Mar; 6():61. PubMed ID: 30221005
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
    Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, Tognim MC.
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4128-39. PubMed ID: 27139468
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG, Morandin E, Baraldo M, Pea F.
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [Abstract] [Full Text] [Related]

  • 34. Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers.
    Edwina AE, Koch BCP, Muller AE, Al Jalali V, Matzneller P, Zeitlinger M, Sassen SDT.
    Eur J Clin Pharmacol; 2023 Jun; 79(6):775-787. PubMed ID: 37060459
    [Abstract] [Full Text] [Related]

  • 35. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 36. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
    Gupta V, Yu KC, Pogue JM, Watts JA, Clancy CJ.
    Microbiol Spectr; 2022 Jun 29; 10(3):e0115822. PubMed ID: 35638777
    [Abstract] [Full Text] [Related]

  • 37. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Hang Y, Chen Y, Xue L, Sun S, Liu L, Gao J, Xie C, Zhang X, Zhu J, Jin J, Miao L.
    Int J Antimicrob Agents; 2018 Mar 29; 51(3):484-487. PubMed ID: 28709989
    [Abstract] [Full Text] [Related]

  • 38. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
    Zhao YC, Zou Y, Xiao YW, Wang F, Zhang BK, Xiang DX, Yu F, Luo H, Sandaradura I, Yan M.
    Infect Dis Ther; 2022 Feb 29; 11(1):201-216. PubMed ID: 34748194
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.